MedTrace Logo

Immunogenicity, Safety, and Tolerability of rF1V-1018 Vaccine in Adults 18 to 55 Years of Age

NCT07207408 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 148

Last updated 2025-10-06

No results posted yet for this study

Summary

This study will evaluate the immunogenicity, safety, and tolerability of rF1V-1018 vaccine

Conditions

  • Prevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersenia Pestis

Interventions

BIOLOGICAL

rF1V-1018

Regimen 1

BIOLOGICAL

rF1V-1018

Regimen 2

BIOLOGICAL

rF1V-1018

Regimen 3

BIOLOGICAL

rF1V-1018

Regimen 4

BIOLOGICAL

rF1V-1018

Regimen 5

BIOLOGICAL

rF1V-1018

Regimen 6

Sponsors & Collaborators

  • United States Department of Defense

    collaborator FED

  • Dynavax Technologies Corporation

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-09-11
Primary Completion
2026-05-29
Completion
2026-10-16
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07207408 on ClinicalTrials.gov